Inovio Pharma buy klostergang
Start price
18.10.17
/
50%
€5.75
Target price
18.10.18
€10.64
Performance (%)
-13.03%
End price
18.10.18
€5.00
Summary
This prediction ended on 18.10.18 with a price of €5.00. The prediction for Inovio Pharma disappointed with a performance of -13.03%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Inovio Pharma | - | - | - | - |
| iShares Core DAX® | 2.112% | -0.367% | 13.466% | 16.854% |
| iShares Nasdaq 100 | -2.197% | -3.794% | 38.426% | 42.934% |
| iShares Nikkei 225® | -1.555% | -7.320% | 18.451% | 2.941% |
| iShares S&P 500 | -0.472% | -2.078% | 27.488% | 41.955% |
According to klostergang what are the pros and cons of Inovio Pharma for the foreseeable future?
Pros
Cons
Probably not worthwhile Investment
Comments by klostergang for this prediction
In the thread Inovio Pharma diskutieren
klostergang stimmt der Outperform-Einschätzung der institutionellen Analysten zu
klostergang stimmt am 18.10.2017 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 11.8$ zu.
Inovio Pharmaceuticals (INO +0.5%) is on the move after hours, up 2.6%, after RBC opened coverage at Outperform on some enthusiasm around the company's treatment for cervical pre-cancers.
VGX-3100 could become the first such nonsurgical treatment, analyst Matthew Eckler says, and successful early trials could mean "big upside."
RBC joins a half-dozen other firms with coverage, all in the Buy column.Messner has a price target of $11, implying 76% upside from today's closing price.
(Laufzeit überschritten)
Stopped prediction by klostergang for Inovio Pharma
Inovio Pharma
Start price
Target price
Perf. (%)
€25.80
30.06.20
30.06.20
-
04.11.21
04.11.21
-72.73%
17.06.21
17.06.21
Probably not worthwhile Investment
Inovio Pharma
Start price
Target price
Perf. (%)
€4.06
14.02.20
14.02.20
€2.00
16.02.20
16.02.20
0.99%
16.02.20
16.02.20
Probably not worthwhile Investment